By InvitationNot Applicable

Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery.

Poland100 participantsStarted 2025-07-01

Plain-language summary

Prehabilitation includes care for patients preparing for surgery. This is a modern approach aimed at increasing the patient's functional capacity before surgery and improving postoperative results. Prehabilitation includes preoperative physical activity, nutritional intervention, psychological support, cessation of stimulants and optimization of laboratory test results. Many studies have shown a positive effect of prehabilitation on postoperative results, mainly reducing the number of postoperative complications and shortening the hospitalization time. The assumed time of prehabilitation is 2-6 weeks, but in the case of oncology patients, the procedure should not be delayed only for the sake of prehabilitation. Our study includes oncology patients with ovarian cancer who are referred for neoadjuvant chemotherapy before interval cytoreductive surgery. The assumption of the study is an intensive course of prehabilitation during neoadjuvant treatment, which should provide significantly better postoperative results.

Who can participate

Age range

18 Years – 80 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with confirmed ovarian cancer * No possibility of performing primary debulking surgery (Fagotti score \> 8 points). Referral patient for neoadjuvant chemotherapy * Consent to participate in the study * Age over 18 years Exclusion Criteria: * Performing primary debulking surgery * Lack of consent to participate in the study * Aletti score \< 4 points in interval debulking surgery * Severe neurological/psychiatric disorders that make contact with the patient difficult

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Frequency of postoperative complications

Timeframe: from surgery for the next 30 days

Length of hospital stay

Timeframe: from surgery to hospital discharge (assessed up to 14 days)

Time to start adjuvant chemotherapy

Timeframe: from discharge from hospital for the next 2 months

Trial details

NCT IDNCT07058753

SponsorMedical University of Silesia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-07-01

View on ClinicalTrials.gov More Ovarian Cancer trials